Evidence map›Paper›PMID 38496583›Full record

ArticlebioRxiv : the preprint server for biology2024

Activation of the imprinted Prader-Willi Syndrome locus by CRISPR-based epigenome editing.

Dahlia Rohm, Joshua B Black, Sean R McCutcheon, Alejandro Barrera, Daniel J Morone, Xander Nuttle, Celine E de Esch, Derek J C Tai, Michael E Talkowski, Nahid Iglesias and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Dahlia RohmDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Joshua B BlackDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Sean R McCutcheonDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Alejandro BarreraCenter for Advanced Genomic Technologies, Duke University, Durham, NC 27708, USA.
Daniel J MoroneDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Xander NuttleCenter for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Celine E de EschCenter for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Derek J C TaiCenter for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Michael E TalkowskiCenter for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Nahid IglesiasDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Charles A GersbachDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Duke University · USBroad Institute · US

Funding

The Duke FUNCTION Center: Pioneering the comprehensive identification of combinatorial noncoding causes of diseaseRM1HG011123 · NHGRI · DUKE UNIVERSITY · PI GREGORY E CRAWFORD, Raluca Gordan · 2020 to 2026
$21.9M
High-Throughput Functional Annotation of Gene Regulatory Elements and Variants Critical to Complex Cellular PhenotypesUM1HG012053 · NHGRI · DUKE UNIVERSITY · PI GREGORY E CRAWFORD, Charles A. Gersbach · 2021 to 2026
$10.7M
University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
Molecular mechanisms and genetic drivers of reciprocal genomic disordersR01HD096326 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI TALKOWSKI, MICHAEL E · 2018 to 2022
$3.5M
Dissecting recurrent microdeletion syndromes using dual-guide genome editingR01NS093200 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GUSELLA, JAMES F · 2015 to 2019
$2.9M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
Engineering Targeted Epigenetic Modifiers for Precise Control of Gene RegulationR01DA036865 · NIDA · DUKE UNIVERSITY · PI CRAWFORD, GREGORY E, GERSBACH, CHARLES A. · 2013 to 2017
$2.6M
Epigenome Editing Technologies for Treating Diverse DiseaseU01AI146356 · NIAID · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2019 to 2022
$1.6M
NHGRI NIH HHS RM1 HG011123NHGRI NIH HHS UM1 HG012053NIAID NIH HHS U01 AI146356NICHD NIH HHS R01 HD096326NIDA NIH HHS R01 DA036865NIGMS NIH HHS T32 GM008555NIGMS NIH HHS T32 GM144291NINDS NIH HHS R01 NS093200
6 · The paper itself

Abstract

Epigenome editing with DNA-targeting technologies such as CRISPR-dCas9 can be used to dissect gene regulatory mechanisms and potentially treat associated disorders. For example, Prader-Willi Syndrome (PWS) is caused by loss of paternally expressed imprinted genes on chromosome 15q11.2-q13.3, although the maternal allele is intact but epigenetically silenced. Using CRISPR repression and activation screens in human induced pluripotent stem cells (iPSCs), we identified genomic elements that control expression of the PWS gene

Identifiers

PMID38496583
PMCPMC10942373
OpenAlexW4392466974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.